Seliger Barbara
Martin-Luther-Universitat Halle-Wittenberg, Institute of Medical Immunology, Halle (Saale), Germany.
J Immunotoxicol. 2008 Oct;5(4):361-7. doi: 10.1080/15476910802482870.
In recent years, progress has been made in understanding how peptides presented by MHC Class I molecules were generated, in particular which proteases are involved in this process and how intracellular pathways influence antigen presentation in professional antigen-presenting cells and various types of tumor cells. This review will give an overview of MHC Class I abnormalities in malignancies and their underlying molecular mechanisms. Dependent on the tumor types structural alterations in particular of the MHC Class I heavy chain, beta(2)-m and the TAP1 subunit have been found at a low frequency, whereas dysregulation of MHC Class I antigen processing components appears to be the major mechanism of MHC Class I down-regulation in tumors of distinct origin. This could occur at the epigenetic, transcriptional and/or post-transcriptional level. The lack or suppression of MHC Class I surface expression due to antigen-processing deficiencies are accompanied by reduced recognition and lysis by antigen-specific cytotoxic T-lymphocytes, which is further often associated with disease progression.
近年来,在理解MHC I类分子呈递的肽段是如何产生方面取得了进展,特别是哪些蛋白酶参与了这一过程,以及细胞内途径如何影响专业抗原呈递细胞和各种类型肿瘤细胞中的抗原呈递。本综述将概述恶性肿瘤中MHC I类异常及其潜在分子机制。根据肿瘤类型,已发现特别是MHC I类重链、β2-微球蛋白和TAP1亚基的结构改变频率较低,而MHC I类抗原加工成分的失调似乎是不同起源肿瘤中MHC I类下调的主要机制。这可能发生在表观遗传、转录和/或转录后水平。由于抗原加工缺陷导致的MHC I类表面表达缺乏或抑制,伴随着抗原特异性细胞毒性T淋巴细胞的识别和裂解减少,这通常还与疾病进展相关。